Literature DB >> 6197458

Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity.

J E de Vries, H Spits.   

Abstract

Activation of peripheral blood lymphocytes (PBL) from a melanoma patient either in secondary MLC in which EBV-transformed B cells from the cell line JY were used as stimulator cells, or by co-cultivation with the autologous melanoma cells in a mixed leukocyte tumor cell culture (MLTC) resulted in the generation of cytotoxic activity against the autologous melanoma (O-mel) cells. From these activated bulk cultures four cloned cytotoxic T lymphocyte (CTL) lines were isolated. The CTL clone O-1 (T3+, T4+, T8-, OKM-1-, HNK-, and HLA-DR+), and O-36 (T3+, T4-, T8+, OKM-, HNK-, and HLA-DR+) were obtained from MLC, whereas the CTLC clones O-C7 (T3+, T4+, T8-, OKM-1-, HNK-, and HLA-DR+) and O-D5 (T3+, T4-, T8+, OKM-1-, HNK, and HLA-DR+) were isolated from autologous MLTC. All four CTL clones were strongly cytotoxic for O-mel cells but failed to lyse autologous fibroblasts and autologous T lymphoblasts. Moreover, the CTL clones lacked NK activity as measured against K562 and Daudi cells. Panel studies indicated that the CTL clones also killed approximately 50% of the allogeneic melanoma cells preferentially, whereas the corresponding T lymphoblasts were not lysed. Monoclonal antibodies against class I (W6/32) and class II (279) MHC antigens failed to block the reactivity of the CTL clones against O-mel and allogeneic melanoma cells, indicating that a proportion of human melanoma cells share determinants that are different from HLA antigens and that are recognized by CTL clones. In contrast to the CTL clones isolated from MLTC, the clones obtained from MLC also lysed JY cells, which initially were used as stimulator cells. The reactivity of O-36 against JY could be inhibited with W6/32, demonstrating that this reactivity was directed against class I MHC antigens. These results suggest that the lysis of O-mel and JY cells by O-36 has to be attributed to two independent specificities of this CTL clone. The specificity of the other cross-reactive CTL clone (O-1) could not be determined. The notion that individual CTL clones can have two specificities was supported by the following observations. The cytotoxic reactivity of both O-1 (T4+) and O-36 (T8+) against JY was blocked by monoclonal antibodies directed against T3 and human LFA-1, and against T3, T8, and human LFA-1, respectively.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6197458

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

Review 1.  Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy.

Authors:  Arvind Chhabra
Journal:  Vaccine       Date:  2010-05-06       Impact factor: 3.641

2.  Induction of auto-logous human cytotoxic T lymphocytes (CTL) from peripheral blood against tumor cells.

Authors:  T Ohno
Journal:  Cytotechnology       Date:  1997-01       Impact factor: 2.058

3.  Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.

Authors:  A Knuth; T Wölfel; E Klehmann; T Boon; K H Meyer zum Büschenfelde
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

4.  Mitogenic stimulation of human tumor-infiltrating lymphocytes by secreted factor(s) from human tumor cell lines.

Authors:  B S Packard
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

5.  Clonal analysis of cytotoxic T lymphocytes (CTL) against autologous melanoma. Classification based on phenotype, specificity and inhibition by monoclonal antibodies to T cell structures.

Authors:  P Hersey; M MacDonald; S Schibeci; C Burns
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes. Implications of a renewable source of precursors for adoptive cellular immunotherapy.

Authors:  C L Slingluff; T L Darrow; H F Seigler
Journal:  Ann Surg       Date:  1989-08       Impact factor: 12.969

7.  Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells.

Authors:  P Allavena; P Lo Presti; M Di Bello; V Lucchini; A Lissoni; G Zanetta; C Mangioni; A Mantovani
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

8.  Propagation of cytotoxic effectors from chronic myeloid leukemia patients and cloning of cytotoxic T cells.

Authors:  R Somasundaram; S H Advani; S G Gangal
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

9.  In vitro generation of effector cells cytotoxic to autologous targets from chronic myeloid leukemia patients in remission.

Authors:  R Somasundaram; S G Rao; S H Advani; S G Gangal
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 10.  Activation of lymphocyte anti-tumour responses in man: effector heterogeneity and the search for immunomodulators.

Authors:  B M Vose
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.